Epclusa is owned by Gilead Sciences Inc.
Epclusa contains Sofosbuvir; Velpatasvir.
Epclusa has a total of 30 drug patents out of which 0 drug patents have expired.
Epclusa was authorised for market use on 10 June, 2021.
Epclusa is available in pellets;oral dosage forms.
Epclusa can be used as for the treatment of hepatitis c.
The generics of Epclusa are possible to be released after 30 July, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(6 years from now) | |
US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(6 years from now) | |
US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(7 years from now) | |
US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(7 years from now) | |
US8940718 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
US8575135 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
US8921341 | GILEAD SCIENCES INC | Antiviral compounds |
Nov, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(5 years from now) | |
US8334270
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
US9085573
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
US8735372
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
US8580765
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(5 years from now) | |
US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(6 years from now) | |
US7964580
(Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(6 years from now) | |
US8889159
(Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(6 years from now) | |
US8633309
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(6 years from now) | |
US9284342
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(8 years from now) | |
US8618076
(Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(8 years from now) | |
US8940718
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
US8921341
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
US8575135
(Pediatric) | GILEAD SCIENCES INC | Antiviral compounds |
May, 2033
(10 years from now) | |
US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(10 years from now) | |
US11116783
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
US10086011
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) | |
US9757406
(Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
M | Apr 27, 2025 |
Pediatric Exclusivity (PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic